Understanding of the multifaceted issues concerned in the use of drugs during pregnancy has lagged far behind the development of knowledge in other areas of therapeutics. This is partly because "thalidomide's long shadow" has slowed research that entails giving a drug to a pregnant woman. ' 9%.7 This may be due largely to the continued attention paid by the news media to drug induced fetal abnormality.8
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Understanding of the multifaceted issues concerned in the use of drugs during pregnancy has lagged far behind the development of knowledge in other areas of therapeutics. This is partly because "thalidomide's long shadow" has slowed research that entails giving a drug to a pregnant woman. ' A further reason is undoubtedly the difficulties (often more imagined than real) in performing interdisciplinary research. None the less, progress is being made, and several monographs on the clinical pharmacology ofpregnancy have recently been published. 2 This series is aimed at practising clinicians who prescribe drugs for women who are, or who may become, pregnant. The emphasis is on the clinically relevant aspects of research performed over the past 10 years or so. There are two introductory articles: one on clinical pharmacology relevant to human pregnancy and the other on identifying fetal abnormality. The series will then cover treatment during pregnancy of: minor ailments, bacterial infections, asthma, thromboembolic disease, psychiatric disorders, rheumatoid arthritis, cardiovascular disorders, endocrine diseases, and epilepsy. 9%.7 This may be due largely to the continued attention paid by the news media to drug induced fetal abnormality. 8 In the puerperium the use of drugs increases substantially.9 10 One study showed that more than 99% of women received at least one drug, often an analgesic, during the first week after delivery.9 This study also found that hypnotics were used by 36% of women in the puerperium. There was no difference in the pattern of prescribing between mothers who were breast feeding and those who were bottle feeding.
Effect of pregnancy on dose requirements
The physiological changes of pregnancy can lead to clinically important reductions in the blood concentrations of certain drugs.
Total body water increases by as much as 8 litres during pregnancy," 12 which provides a substantially increased volume within which drugs can be distributed.
Serum proteins relevant to drug binding undergo considerable changes in concentration. 3 Albumin, which binds acidic drugs such as phenytoin, decreases in concentration by up to 10 g/l. 14 The main implication of this change is in the interpretation of drug concentrations, which is discussed below.
Liver metabolism increases during pregnancy,'5 but liver blood flow does not. ' The major consequence of these physiological changes is that some drugs-notably, anticonvulsants and theophylline derivatives -can undergo changes in distribution and elimination which lead to ineffective treatment because of inadequate drug concentrations in the blood.
Therapeutic drug monitoring during pregnancy
Among the drugs for which plasma concentrations would normally be measured those most likely to be encountered during pregnancy are anticonvulsants and theophylline derivatives. Because important changes in concentration may occur drug concentrations should be measured at monthly intervals throughout pregnancy and again one week and four weeks after delivery. The dose required usually increases as gestation progresses, particularly in the third trimester, and decreases in the puerperium. The increase may be large-for example, a patient who is normally well controlled taking 300 mg of phenytoin a day may require 600 mg a day by the end of pregnancy just to stay at the bottom of the therapeutic range.
Two points should be considered when interpreting drug concentrations during pregnancy.
Protein binding-The reduction in albumin concentration during pregnancy leads to a decrease in the measured concentrations of drugs which are highly bound, such as phenytoin. The increased amount of drug which is unbound will, however, be available for both distribution out of the blood and for elimination from the body. The net result of the change in albumin concentration on phenytoin is that the total level falls but the free level is virtually unchanged. Only the free (unbound) drug is pharmacologically active, and so if the laboratory gives drug concentrations as total drug the therapeutic range should be revised downwards. As a rule of thumb, the concentration of the drug should be kept at the bottom of the usual therapeutic range.
Therapeutic range-It is not clear whether pregnancy alters the effects of drugs. This is an important matter, but one which is difficult to study. Apart from the pharmacokinetic considerations Passage of drugs to the fetus Much of the published work on the transfer of drugs across the placenta is concerned with the rate of transfer, but except in the context of single doses-for example, at the time of delivery-this is not the major issue. The placenta is essentially a lipid barrier between the maternal and fetal circulations. Drugs cross the placenta by passive diffusion. A lipid soluble, un-ionised drug of low molecular weight will cross the placenta more rapidly than a more polar drug. Given time, however, most drugs will achieve roughly equal concentrations on each side of the placenta. For example, after a single dose of indomethacin the ratio of cord to maternal plasma concentration is 0 5:1 at two hours but 1:1 at five hours.2I A similar example is provided by the blockers. Researchers thought that a polar drug like atenolol might have limited transfer to the fetus, but on long term dosing this was found not to be the case. 22 Thus the practical view to take when prescribing drugs during pregnancy is that transfer of drugs to the fetus is inevitable. The only notable exception to this rule is heparin, which is so large and so polar that its transfer across the placenta is negligible.
Breast feeding
As with the transfer of drugs across the placenta, much has been written on the theoretical aspects of passage of drugs into breast milk, but the relevance of these publications is equally doubtful. Virtually all drugs cross into breast milk. Previous dilution in the mother's body, however, coupled with the volume of milk consumed usually mean that the dose administered to the baby is clinically unimportant.
There are three main categories of drugs so far as breast feeding is concerned.
(1) Drugs which are undetectable in the baby. These include warfarin, which is so highly bound to maternal proteins that it is undetectable even in breast milk,23 and aminoglycosides, which are not absorbed from the gastrointestinal tract of normal infants. 24 (2) Drugs which reach the baby but in an insignificant dose. These include most drugs used in everyday practice: non-narcotic analgesics,25 non-steroidal anti-inflammatory drugs, 26 harm must come to the mother or baby because a disease is being inadequately treated. The aim of this series is to provide the information on which a clinical decision can be made.
